GlassScriptPhysician profile
Fabian Lugo
NPI 1538190798
$26,517.01
in general payments reported to CMS, 2019-2025
61 companies · $4,300 in 2025
The $4,300 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,999 · 2020: $3,048 · 2021: $3,795 · 2022: $3,745 · 2023: $4,072 · 2024: $4,559 · 2025: $4,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,831.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,241.27 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $2,289.31 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,869.58 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $1,631.06 | 2019-2025 | Nuplazid |
| Biogen, INC. | $1,412.47 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Eisai INC. | $1,209.85 | 2019-2025 | |
| Sk Life Science, INC. | $1,098.55 | 2020-2025 | Xcopri |
| Lundbeck LLC | $940.53 | 2019-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $864.29 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $861.63 | 2019-2024 | Ajovy, Austedo |
| Amneal Pharmaceuticals LLC | $858.37 | 2019-2025 | Rytary, Crexont |
| Amgen INC. | $732.26 | 2019-2025 | Repatha, Uplizna |
| Lilly USA, LLC | $729.19 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Alexion Pharmaceuticals, INC. | $712.36 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $678.37 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabian Lugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.